US prescription drug spending will top $560 billion in 2026, according to current projections. This would represent an 8.2% increase from the previous year. Growing demand for obesity and diabetes treatments is partly driving this rise. These include a new generation of GLP-1 medicines. Projections show prescription medicines outpacing all other major categories of healthcare spending in the US. Their…
Tag: GLP-1 drugs
-
South African Retail Pharmacy: Clicks Versus Dis-Chem
The battle for consumer loyalty in the South African retail pharmacy sector has reached a fierce new level. Market leaders Clicks and Dis-Chem are competing intensely for market share. Tough economic conditions are squeezing middle-income households. This has forced both brands to step up their promotional activities. Traditional retailers are also expanding into the health and beauty space, adding to…
-
Aspen secures licensing agreement to enter GLP-1 market
Aspen Pharmacare’s CEO, Stephen Saad, has celebrated the company’s new licensing agreement to enter the rapidly expanding GLP-1 agonist market. He said this milestone marks a “significant coup” for the company, enabling it to prepare for the market by 2026 and capitalise on the anticipated demand for diabetes and obesity treatment solutions. The global GLP-1 market, driven by increased demand…
-
As competition heats up, Novo Nordisk’s share price declines
Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…